Artiva Biotherapeutics, Inc. Earnings Per Share (Basic)
Artiva Biotherapeutics, Inc. (ARTV) reported Earnings Per Share (Basic) of -$0.63 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.63.
- Artiva Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.95.
- Artiva Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.85.
- Artiva Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.88.
- Artiva Biotherapeutics, Inc. earnings per share, basic for fiscal 2025 was -$3.43.
- Artiva Biotherapeutics, Inc. earnings per share, basic for fiscal 2024 was -$5.81.
- Artiva Biotherapeutics, Inc. earnings per share, basic for fiscal 2023 was -$35.78.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.63 10-Q · filed 2026-08-06 | -$1.51 10-Q · filed 2026-08-06 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.95 10-Q · filed 2026-05-08 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.68 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.55 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$1.72 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$2.60 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.43 10-K · filed 2026-03-10 |
| 2025-09-30 | -$0.88 10-Q · filed 2025-11-12 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.59 10-Q · filed 2025-11-12 | -$3.25 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.87 10-Q · filed 2026-08-06 | -$1.71 10-Q · filed 2026-08-06 | -$2.37 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.27 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.83 10-Q · filed 2026-05-08 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.39 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.19 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$3.50 derived: net income ÷ weighted average shares · filed 2026-03-10 | -$5.81 10-K · filed 2026-03-10 |
| 2024-09-30 | -$0.92 10-Q · filed 2025-11-12 | -$3.58 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$7.16 10-Q · filed 2025-11-12 | -$11.49 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$22.00 10-Q · filed 2025-08-06 | -$39.24 10-Q · filed 2025-08-06 | -$54.07 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$40.19 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$17.24 10-Q · filed 2025-05-08 | -$32.07 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$18.16 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$32.19 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$14.82 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$14.90 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$35.78 10-K · filed 2025-03-24 |
| 2023-09-30 | $13.98 10-Q · filed 2024-11-12 | -$0.01 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$20.89 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$14.09 10-Q · filed 2024-08-29 | -$35.12 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |